Sugi Predict

Sugi Predict / Compounds / SCHEMBL3692167

SCHEMBL3692167

SCHEMBL3692167

COc1ccc2c(c1)CCCNC2=O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GRM5 P41594 1/20 0.56
▸ KDR P35968 1/20 0.52
▸ PARP10 Q53GL7 2/20 0.51
▸ PARP11 Q9NR21 2/20 0.51
▸ RYR2 Q92736 1/20 0.51
▸ MAPKAPK2 P49137 2/20 0.51
▸ CDK1 P06493 1/20 0.51
▸ CYP19A1 P11511 3/20 0.47
▸ CYP11B2 P19099 2/20 0.47
▸ METAP1 P53582 1/20 0.46
▸ PRKD1 Q15139 1/20 0.46
▸ ALDH1A1 P00352 2/20 0.46
▸ MAPT P10636 2/20 0.46
▸ MIF P14174 2/20 0.46
▸ PARP1 P09874 1/20 0.46
▸ LMNA P02545 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ KDM4E B2RXH2 1/20 0.45
▸ HPGD P15428 1/20 0.45
▸ MTNR1A P48039 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8323443 0.90 GRM5 (0.67) GRM5PARP10PARP11RYR2MAPKAPK2
SCHEMBL379341 0.90 GRM5 (0.67) GRM5PARP10PARP11RYR2MAPKAPK2
SCHEMBL1649500 0.88 MAPKAPK2 (0.57) GRM5KDRPARP10RYR2MAPKAPK2
SCHEMBL23160638 0.84 PARP1 (0.49) GRM5PARP10PARP11CYP19A1CYP11B2
SCHEMBL23160292 0.82 PARP10 (0.47) GRM5PARP10PARP11ALDH1A1MAPT
SCHEMBL29758907 0.82 PARP10 (0.47) GRM5PARP10PARP11ALDH1A1MAPT
SCHEMBL12018689 0.81 CYP19A1 (0.47) KDRCYP19A1CYP11B2ALDH1A1MAPT
SCHEMBL12077584 0.81 RYR2 (0.51) GRM5KDRPARP10PARP11RYR2
SCHEMBL23160144 0.81 CES1 (0.48) GRM5PARP10PARP11PARP1
SCHEMBL2023021 0.80 PDE3B (0.57) GRM5KDRRYR2MAPKAPK2CYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115724799-B Potassium channel regulator, composition and application 纽欧申医药(上海)有限公司 2025-05-13 — — CN disclosed
US-20240051951-A1 BICYCLIC COMPOUND AND USE THEREOF SK BIOPHARMACEUTICALS CO., LTD. (KR) 2024-02-15 — — US disclosed
US-20230286965-A1 BICYCLIC COMPOUND AND USE THEREOF SK BIOPHARMACEUTICALS CO., LTD. (KR) 2023-09-14 — — US disclosed
US-11725001-B2 Bicyclic compound and use thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2023-08-15 — — US disclosed
CN-115724799-A Potassium channel regulator, composition and application 杭州和正医药有限公司 2023-03-03 — — CN disclosed
US-20220402902-A1 BICYCLIC COMPOUND AND USE THEREOF SK BIOPHARMACEUTICALS CO., LTD. 2022-12-22 — — US disclosed
EP-4039686-A1 BICYCLIC COMPOUND AND USE THEREOF SK Biopharmaceuticals Co., Ltd. (KR) 2022-08-10 — — EP disclosed
US-11180482-B2 Anilinopyrimidines as haematopoietic progenitor kinase 1 (HPK1) inhibitors ARIAD PHARMACEUTICALS, INC. (US) 2021-11-23 — — US disclosed
US-11111237-B2 Bicyclic compound and use thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2021-09-07 — — US disclosed
WO-2021066578-A1 BICYCLIC COMPOUND AND USE THEREOF 에스케이바이오팜 주식회사 2021-04-08 — — WO disclosed
EP-1562595-A1 DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2005-08-17 — — EP disclosed
EP-1539704-A1 SUBSTITUTED AZEPINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES ELI LILLY AND COMPANY (US) 2005-06-15 — — EP disclosed
US-20040167119-A1 2-(aminomethyl) arylamide analgesics PHARMACOPEIA, INC (US) 2004-08-26 — — US disclosed
WO-2004071445-A2 2-(AMINOMETHYL)ARYLAMIDE ANALGESICS PHARMACOPEIA DRUG DISCOVERY, INC. (US) 2004-08-26 — — WO disclosed
WO-2004071445-A2 2-(AMINOMETHYL)ARYLAMIDE ANALGESICS PHARMACOPEIA DRUG DISCOVERY, INC. (US) 2004-08-26 — — WO disclosed
WO-2004069256-A1 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF NOVARTIS AG (CH) 2004-08-19 — — WO disclosed
WO-2004069256-A1 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF NOVARTIS AG (CH) 2004-08-19 — — WO disclosed
WO-2004065351-A1 AMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 NOVARTIS AG (CH) 2004-08-05 — — WO disclosed
WO-2004026305-A1 DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONIST ELI LILLY AND COMPANY (US) 2004-04-01 — — WO disclosed
WO-2004018432-A1 SUBSTITUTED AZEPINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES ELI LILLY AND COMPANY (US) 2004-03-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220402902-A1 BICYCLIC COMPOUND AND USE THEREOF PRMT5, PRMT6, PRMT1 GRM5 97/4885KDR 2955/4885PARP10 58/4885
US-11111237-B2 Bicyclic compound and use thereof PRMT5, PRMT6, PRMT1 GRM5 97/4885KDR 2955/4885PARP10 58/4885
US-20240051951-A1 BICYCLIC COMPOUND AND USE THEREOF PRMT5, PRMT6, PRMT1 GRM5 97/4885KDR 2955/4885PARP10 58/4885
US-20230286965-A1 BICYCLIC COMPOUND AND USE THEREOF PRMT5, PRMT6, PRMT8 GRM5 144/4885KDR 3028/4885PARP10 78/4885
US-11725001-B2 Bicyclic compound and use thereof PRMT5, PRMT6, PRMT1 GRM5 97/4885KDR 2955/4885PARP10 58/4885
US-11180482-B2 Anilinopyrimidines as haematopoietic progenitor kinase 1 (HPK1) inhibitors STK16, STK4, STK26 GRM5 3464/4885KDR 1457/4885PARP10 991/4885
US-20040167119-A1 2-(aminomethyl) arylamide analgesics OPRL1, OPRM1, OPRK1 GRM5 217/4885KDR 4390/4885PARP10 2937/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.